Overview

• Class action lawsuits have been filed against SCYNEXIS, Inc. for alleged violations of federal securities laws between March 31, 2023, and September 22, 2023.
• The lawsuits claim that SCYNEXIS made materially false and misleading statements, and failed to disclose material adverse facts about the company's business, operations, and prospects.
• Specifically, it is alleged that SCYNEXIS did not disclose that the equipment used to manufacture its drug ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination.
• The company is also accused of not having effective internal controls and procedures, and adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP).
• Due to the substantial risk of cross-contamination, it is alleged that SCYNEXIS was reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies.